No increased risk of heart disease with integrase inhibitors in HIV patients
Author Information
Author(s): García-Abellán Javier, García José A, Padilla Sergio, Fernández-González Marta, Agulló Vanesa, Mascarell Paula, Botella Ángela, Gutiérrez Félix, Masiá Mar
Primary Institution: Hospital General Universitario de Elche and Universidad Miguel Hernández de Elche, Alicante, Spain
Hypothesis
Does the use of integrase strand transfer inhibitors (INSTI) lead to increased progression of subclinical atherosclerosis compared to non-nucleoside reverse transcriptase inhibitors (NNRTI) in people with HIV?
Conclusion
INSTI-based regimens are not associated with increased progression of subclinical atherosclerosis when compared to NNRTI.
Supporting Evidence
- 190 participants were recruited and 173 completed the 96 week follow-up.
- 87 participants experienced a cIMT increase ≥ 10%, with 54 developing a new carotid plaque.
- Adjusted analyses showed no significant differences in cIMT progression between treatment groups.
Takeaway
This study looked at people with HIV taking different medications and found that those on integrase inhibitors didn't have more heart problems than those on other medications.
Methodology
A prospective study measuring carotid intima-media thickness (cIMT) in HIV patients on INSTI or NNRTI regimens over 96 weeks.
Potential Biases
Participants receiving both INSTI and NNRTI may have influenced the results.
Limitations
The study was non-randomized and had a relatively small sample size.
Participant Demographics
Median age was 48 years, with 81.1% male and 59% having at least one cardiovascular risk factor.
Statistical Information
P-Value
0.647
Confidence Interval
−0.031 to 0.103
Statistical Significance
p=0.647
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website